Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kyle T Amber

Showing results (21-30 of 141) with videos related to

Pageof 15
Sort By:
The British Journal of Dermatology|June 24, 2024
The safety of topical vs. oral steroids in bullous pemphigoid: considerations for retrospective analysesKyle T Amber, Ron J Feldman
Journal of the American Academy of Dermatology|July 16, 2021
The risk of Pneumocystis pneumonia in patients of autoimmune blistering disease-reply to letter entitled "Pemphigus management guidelines: A life-saving perspective"Payal M Patel, Kyle T Amber
Journal of the American Academy of Dermatology|October 10, 2025
Response to Cao et al, "Efficacy, safety, and B-cell depletion capacity of 3 rituximab dosing regimens in the treatment of moderate-to-severe pemphigus vulgaris and pemphigus foliaceus: A 52-week clinical trial"Sabrina F Schundler, Kyle T Amber
American Journal of Clinical Dermatology|September 21, 2015
Second Primary Malignancies in CTCL Patients from 1992 to 2011: A SEER-Based, Population-Based Study Evaluating Time from CTCL Diagnosis, Age, Sex, Stage, and CD30+ SubtypeKyle T Amber, Romi Bloom, Keyvan Nouri
The Journal of Clinical and Aesthetic Dermatology|July 12, 2014
Injection therapy for the management of superficial subcutaneous lipomasKyle T Amber, Steven Ovadia, Ivan Camacho
JAMA Dermatology|January 15, 2016
Association of Google Search Volume Index Peaks for Skin Cancer With Skin Cancer Awareness Month--ReplyKyle T Amber, Romi Bloom, Shasa Hu
International Journal of Dermatology|April 14, 2023
Diversity in autoimmune blistering disease clinical trials: a systematic reviewConnor Cole, Roger Haber, Kyle T Amber
Antibodies (Basel, Switzerland)|July 27, 2022
Deciphering the Contribution of BP230 Autoantibodies in Bullous PemphigoidConnor Cole, Luca Borradori, Kyle T Amber
Italian Journal of Dermatology and Venereology|November 12, 2020
Autoreactive T cells in pemphigus: perpetrator and targetLuca Scarsella, Robert Pollmann, Kyle T Amber
Lung|April 24, 2015
A Systematic Review of Patients with Mucocutaneous and Respiratory Complications in Paraneoplastic Autoimmune Multiorgan Syndrome: Castleman's Disease is the Predominant MalignancyJohn Lee, Romi Bloom, Kyle T Amber
Pageof 15

Showing results (21-30 of 141) with videos related to

Sort By:
Pageof 15
The British Journal of Dermatology|June 24, 2024
The safety of topical vs. oral steroids in bullous pemphigoid: considerations for retrospective analysesKyle T Amber, Ron J Feldman
Journal of the American Academy of Dermatology|July 16, 2021
The risk of Pneumocystis pneumonia in patients of autoimmune blistering disease-reply to letter entitled "Pemphigus management guidelines: A life-saving perspective"Payal M Patel, Kyle T Amber
Journal of the American Academy of Dermatology|October 10, 2025
Response to Cao et al, "Efficacy, safety, and B-cell depletion capacity of 3 rituximab dosing regimens in the treatment of moderate-to-severe pemphigus vulgaris and pemphigus foliaceus: A 52-week clinical trial"Sabrina F Schundler, Kyle T Amber
American Journal of Clinical Dermatology|September 21, 2015
Second Primary Malignancies in CTCL Patients from 1992 to 2011: A SEER-Based, Population-Based Study Evaluating Time from CTCL Diagnosis, Age, Sex, Stage, and CD30+ SubtypeKyle T Amber, Romi Bloom, Keyvan Nouri
The Journal of Clinical and Aesthetic Dermatology|July 12, 2014
Injection therapy for the management of superficial subcutaneous lipomasKyle T Amber, Steven Ovadia, Ivan Camacho
JAMA Dermatology|January 15, 2016
Association of Google Search Volume Index Peaks for Skin Cancer With Skin Cancer Awareness Month--ReplyKyle T Amber, Romi Bloom, Shasa Hu
International Journal of Dermatology|April 14, 2023
Diversity in autoimmune blistering disease clinical trials: a systematic reviewConnor Cole, Roger Haber, Kyle T Amber
Antibodies (Basel, Switzerland)|July 27, 2022
Deciphering the Contribution of BP230 Autoantibodies in Bullous PemphigoidConnor Cole, Luca Borradori, Kyle T Amber
Italian Journal of Dermatology and Venereology|November 12, 2020
Autoreactive T cells in pemphigus: perpetrator and targetLuca Scarsella, Robert Pollmann, Kyle T Amber
Lung|April 24, 2015
A Systematic Review of Patients with Mucocutaneous and Respiratory Complications in Paraneoplastic Autoimmune Multiorgan Syndrome: Castleman's Disease is the Predominant MalignancyJohn Lee, Romi Bloom, Kyle T Amber
Pageof 15